Search

Displaying results 6711 - 6720 of 7893 in total
  1. Drug

    Gavocabtagene autoleucel

    go.drugbank.com/drugs/DB17367
    Investigational

    Gavocabtagene autoleucel is a novel cell therapy consisting of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit

  2. Drug

    KAHR-102

    go.drugbank.com/drugs/DB17427
    Investigational

    KAHR-102 is a dual signaling protein fusing cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to the Fas-ligand (FasL).

  3. Drug

    BI-1206

    go.drugbank.com/drugs/DB17429
    Investigational

    BI-1206 is a fully human immunoglobulin G1 monoclonal antibody that targets CD32b.

  4. Drug

    TEL540-548

    go.drugbank.com/drugs/DB17461
    Investigational

    TEL540-548 is a recombinant peptide consisting of the amino acid residues 540 to 548 of the human telomerase reverse transcriptase (hTERT).

  5. Drug

    Disomotide

    go.drugbank.com/drugs/DB17469
    Investigational

    Disomotide is a synthetic peptide cancer vaccine.

  6. Drug

    6-diazo-5-oxo-L-norleucine

    go.drugbank.com/drugs/DB17537
    Investigational

    6-diazo-5-oxo-L-norleucine is a broad-acting glutamine antagonist.

  7. Drug

    PLX51107

    go.drugbank.com/drugs/DB17543
    Investigational

    PLX51107 is a potent and selective inhibitor of the bromodomain and extraterminal (BET) protein family.

    Synonyms: Benzoic acid, 4-(6-(3,5-dimethyl-4-isoxazolyl)-1-((1s)-1-(2-pyridinyl)ethyl)-1h-pyrrolo(3,2-b)pyridin-3-yl)-
  8. Drug

    Timdarpacept

    go.drugbank.com/drugs/DB17544
    Investigational

    IMM01 is a recombinant human signal regulatory protein α (SIRPα) IgG 1 fusion protein. … [A257261] IMM01 is under investigation in clinical trial NCT05140811 (A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome).

  9. Drug

    Jaktinib

    go.drugbank.com/drugs/DB17545
    Investigational

    Jaktinib is a JAK 1, JAK 2 and JAK 3 inhibitor, being developed by Suzhou Zelgen Biopharmaceuticals.

  10. Drug

    Anzurstobart

    go.drugbank.com/drugs/DB17547
    Investigational

    Anzurstobart is a monoclonal antibody directed against signal-regulatory protein alpha (SIRPα) on monocytes and macrophages to potently block the CD47-SIRPα interaction.